The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Improved disease-free survival with intraportal chemotherapy plus adjuvant chemotherapy (mFOLFOX6) as adjuvant treatment in colon cancer.
Wenju Chang
No relevant relationships to disclose
Jianmin Xu
No relevant relationships to disclose
Ye Wei
No relevant relationships to disclose
Li Ren
No relevant relationships to disclose
Tianshu Liu
No relevant relationships to disclose
Jingwen Chen
No relevant relationships to disclose
Dexiang Zhu
No relevant relationships to disclose
Qi Lin
No relevant relationships to disclose
Xinyu Qin
No relevant relationships to disclose